You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
Express Scripts
McKesson
Moodys

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 9,713,572

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,713,572
Title:Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PERJETA (pertuzumab), ACTEMRA (tocilizumab), KADCYLA (trastuzumab emtansine), MetMAb (onartuzumab), obinutuzumab, ocrelizumab or lebrikizumab.
Inventor(s): Weeks; Wendell P. (Corning, NY), Schaut; Robert Anthony (Painted Post, NY), DeMartino; Steven Edward (Painted Post, NY), Peanasky; John Stephen (Big Flats, NY)
Assignee: Corning Incorporated (Corning, NY)
Application Number:14/259,255
Patent Claims:see list of patent claims

Details for Patent 9,713,572

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Corning Incorporated (Corning, NY) 2033-04-24 RX search
Genentech Inc OCREVUS ocrelizumab INJECTABLE;INJECTION 761053 001 2017-03-28   Start Trial Corning Incorporated (Corning, NY) 2033-04-24 RX search
Genentech GAZYVA obinutuzumab INJECTABLE;INJECTION 125486 001 2013-11-01   Start Trial Corning Incorporated (Corning, NY) 2033-04-24 RX Orphan search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Corning Incorporated (Corning, NY) 2033-04-24 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Start Trial Corning Incorporated (Corning, NY) 2033-04-24 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 003 2010-01-08   Start Trial Corning Incorporated (Corning, NY) 2033-04-24 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 002 2010-01-08   Start Trial Corning Incorporated (Corning, NY) 2033-04-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Baxter
McKinsey
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.